MS Academia: Multiple sclerosis advanced course
|
|
- Jordan Parsons
- 6 years ago
- Views:
Transcription
1 6 October Barcelona, Spain MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION
2 Mark S. Freedman University of Ottawa and the Ottawa Hospital Research Institute Ottawa, Ontario, Canada Receipt of research or educational grants: None Receipt of honoraria or consultation fees: BayerHealthcare, BiogenIdec, Chugai, EMD Canada, Genzyme, Novartis, Opexa, Roche, Sanofi-Aventis, Teva Canada Innovation Member of a company advisory board, board of directors or other similar group: Actelion, BiogenIdec, Chugai, Genzyme, Merck Serono, Novartis, Opexa, Sanofi-Aventis Participation in a company sponsored speaker s bureau: Genzyme 2
3 6 October Barcelona, Spain Efficacy profile of existing treatments M.S. Freedman IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION
4 Patient Profiles for Treatment Newly diagnosed, treatment naïve 1 Patients considering other DMTs because of tolerability issues or ongoing side effects 1,2 Patients who discontinued other DMTs because of dosing or adherence difficulties 1,2 Patients who discontinued other DMTs because of lack of efficacy Considered together Would these different patients warrant a different efficacy profile? 1. Wingerchuk DM, Carter JL. Mayo Clin Proc. 2014;89: Devonshire V et al. Eur J Neurol. 2011;18:69-77.
5 Goals of MS Therapy 1. Treatments. Accessed May 16, 2013
6 Goals of Treatment The best option is one that hits consistently on all outcome measures Slowing EDSS Progression Reducing Relapses Reducing MRI Activity
7 Current MS Therapies Injectables: Interferon- 1a, Interferon- 1b Glatiramer acetate Monoclonal antibodies: Natalizumab Alemtuzumab Oral treatments Fingolimod Dimethyl fumarate Teriflunomide
8 Emerging MS Therapies Oral treatments: Other S-1-P receptor agonists Ponesimod, Siponimod, Ceralifimod Laquinimod Monoclonal antibodies: Daclizumab Ocrelizumab, Ofatumumab Secukinumab Cell-based treatments Abilit-T autologous T cell vaccination treatment (SPMS) BMT & autologous stem cell transplantation Mesenchymal stem cell transplantation
9 Choosing a Therapy for a Patient Treatment is for the long term Balancing benefits vs. risks Source of data: Clinical trials + extension Registries Real world Ultimate goal: to use group data to try and predict the response of a single patient over time
10 Responders vs. Non-Responders How do you distinguish between these? True Responders NEDA due to treatment effect These can easily be defined as they are having the events (relapse, MRI or progression) False Responders NEDA due to natural history Non- Responders Continued disease activity despite treatment
11 Response to Treatment Clinical trial data produces group means and 95% confidence intervals but where does the individual patient lie? Placebo % CI: mg % CI: % 6% Reduction 14 mg % CI: Annualized relapse rate N Engl J Med 2012;365:
12 Comparing Efficacy Across Trials: Which to Use? Absolute (ARR) vs. Relative Risk Reduction (RRR) If all populations are at the same risk of having a relapse then RRR should be constant If high risk patients are selected for trials but their risk for relapse is lower then can you reliably use RRR? In such cases, using the ARR and NNT may be a more accurate comparator When event rates become very low, even absolute differences start to lose meaning as they must take into account efficacy and the infrequency of the event
13 Clinical Trial Outcome Measures Why can t we simply compare outcome measures across trials to know which is better? Trial designs differ Outcome definitions (relapse, progression) Frequency of clinical exams or MRI Statistical analysis Reference population (placebo) differ Which outcome measure do we use? Relative reduction to a placebo group Absolute reduction (expected irrespective of a placebo group)
14 Annualized Relapse Rate Absolute vs. Relative Risk Reduction 1,6 1,4 1,2 1 0,8 0,6 0,4 0,2 0 NNT = % Relative =.75 Absolute NNT = 2 Placebo Treatment 50% Relative =.5 Absolute NNT = 4 50% Relative =.25 Absolute Drug X Drug Y Drug Z Which drug is shows showing the most the greatest convincing efficacy? effect? NNT, number needed to treat = (1/absolute reduction)
15 Annualized Relapse Rate Absolute vs. Relative Risk Reduction NNT 2 for both drugs % Relative =.41 Absolute Placebo Treatment % Relative =.5 Absolute IFNDrug -1a sc X Natalizumab Drug Z NNT, number needed to treat = (1/absolute reduction)
16 Annualized Relapse Rate Absolute vs. Relative Risk Reduction NNT = 5 for both drugs 0,6 0,5 36% Relative =.2 Absolute Placebo Treatment 0,4 0,3 50% Relative =.2 Absolute 0,2 0,1 0 Teriflunomide Drug X Dimethyl Drug Fumarate Y NNT, number needed to treat = (1/absolute reduction)
17 Clinical Trial Outcome Measures Primary outcome: relapses Protocol defined, severity not specified Usually reported as annualized rate Does not differentiate among patients with 1 or >1 relapses Secondary outcomes: All independent of relapses EDSS progression MRI PRO (QoL) Duration: 2 years What happens after 2 years?
18 Study Agent Comparison of Main Outcome Measures in Established Treatments IFN -1b IFN -1a IFN 1a Glatiramer 250 g 30 g im qw 44 g sc tiw Acetate ARRR 34% 18% 32% 29% Absolute RRR Relative Reduction in new T2 & Gd+ MRI Activity Relative Reduction in EDSS Progression Absolute Reduction in Proportion Progressing 83% 52% 78% 30% 29%* 37% 30% 12%* 8%* 13% 11% 3%* *p= ns
19 Comparison of Main Outcome Measures in More Recent Treatments Study Agent Natalizumab Fingolimod Teriflunomide Dimethyl Fumarate ARRR 68% 54% 31% 53% Absolute RRR Relative Reduction in new T2 & Gd+ MRI Activity Relative Reduction in EDSS Progression Absolute Reduction in Proportion Progressing 83% 92% 74% 82% 67% 85%* 90%* 42% 30% 30% 38% 12% 6.4% 7.1% 11% *MRI studies performed on 43% of patients
20 Effect of BP Lowering Agents ACE inhibitor trial of BP reduction Mean BP change between treated & placebo groups = 3 mm Hg This has little clinical meaning in and of itself Kaplan Meier Estimates of the Composite Outcome of Myocardial Infarction, Stroke, or Death from Cardiovascular Causes in the ACE treated Group and the Placebo Group N Engl J Med 2000;342:
21 EDSS Progression In Pivotal Trials Agent Study Control Statistically Significant Benefit? p values GA COP-1 Placebo NO p=0.11 sc IFN -1a PRISMS Placebo YES p<0.05 im IFN -1a MSCRG Placebo YES p=0.02 IFN -1b IFNB-1a Placebo NO p=0.161 Alemtuzumab CARE MS-I s.c. IFN-β1a NO p=0.22 CARE MS-II s.c. IFN-β1a YES p=0.008 BG-12 DEFINE Placebo YES p=0.005 CONFIRM Placebo NO p=0.25 Fingolimod FREEDOMS I Placebo YES p=0.02 FREEDOMS II Placebo NO p=0.25 Natalizumab AFFIRM Placebo YES p<0.001 Teriflunomide TEMSO Placebo YES p=0.03 (14 mg) TOWER Placebo YES P=0.04
22 What is the Key Goal of All Therapies? Restricted to wheelchair Bedridden Death Need for walking assistance Normal Neurologic exam Some limitation in walking ability Minimal disability EDSS
23 What is the Key Goal of All Therapies? Preventing or delaying disability How good are short term measures of relapse or MRI activity predictive of longer term benefit? So much depends then on the quality of the relapse or the MRI change Similarly, short term EDSS progression can be qualitatively different depending on where on the scale the progression takes place
24 Is There Evidence for Treatment of Relapses & MRI Changing the Course of Progressive MS? How much does a treatment effect on relapses predict an effect on EDSS progression? The equation predicts for instance, if there is a 50% relative reduction in ARR one can expect a 30% relative reduction in the risk of EDSS worsening How much does a treatment effect on MRI predict an effect on EDSS progression? The equation predicts for instance, if there is a 50% relative reduction in MRI markers one can expect a 5% relative reduction in the risk of EDSS worsening Sormani M et al. Neurology 2010;75:
25 Cumulative probability Long-term benefit of treatment with IFN-β Cumulative probability Propensity scores for important progression milestones Untreated group Treatment group p< p< Time to SPMS Time to EDSS 6 (years) Trojano M et al. Ann Neurol 2007;61:300 6
26 Relapse Events in MS: What are Their Meaning? Are they all the same? Do they all contribute equally to disease? Is there a surrogate for severity? Steroid use Hospitalization Change in EDSS, SNRS, ADL, or other scale Are those with complete recovery different from those without? How significant is a reduction in relapse rate of <0.2 per annum? (1 attack every 5 years)
27 MRI Events in MS MRI Activity measures New or persistent CEL New or enlarging T2 Burden of disease T2 T1 black holes Atrophy MTR/MRS/DTI (exploratory outcomes)
28 MRI Events in MS: What are their meaning? Baseline burden/activity: A small increase over a small baseline vs. small increase over a high baseline does it matter Timing, overall volume, Gd+ or # of lesions: New lesion rate, large vs. small lesions, Gd+ vs. Gd-, or # of new lesions and their location does it matter? Scan Frequency: The more MRI scans performed, the more lesions there are to count - does it matter?
29 PRO Events in MS: What are their meaning? Quality of Life: Different scales, populations, subjective Employment Ability to maintain gainful employment Family Care of children Able to participate in family events Maintenance of the home
30 Events in MS: What are their meaning? Are they all inter-related? Is an attack associated with new MRI activity different from one without MRI change? Do attacks associated with MRI activity but no change in EDSS count for anything? Is time a factor? How often they occur/time? How quickly they occur?
31 Current MS Disease Measures Efficacy currently determined based on independent effects on relapse, MRI or EDSS Would a relapse associated with both MRI and EDSS change be more significant? Likely to be extremely few in current trials, since it would be driven by the event with lowest frequency (i.e. EDSS) What if efficacy was based on preventing events? What is the meaning of being free of a relapse? Relapse-free would have to also imply no activity in other measures (MRI or EDSS progression)
32 No Evidence of Disease Activity (NEDA): A New Metric Given our inability to distinguish meaning among the current MS metrics the simplest way to equalize them is to acknowledge that: they re all bad - but they may not be or more accurately: they can t be good so being free of them is probably a good thing But being free of one but not the others would make no sense (i.e. someone who is free of relapses but had significant EDSS change is counter-intuitive)
33 Striving for NEDA NEDA = no evidence of disease activity No relapse, progression or MRI activity Does not take into account patient factors such as fatigue, cognition, depression NEDA 3 vs. NEDA 4 Concept that MRI atrophy might add something but not widely accepted or available Laudable goal, but hard to achieve over time Important goal especially in the short term
34 NEDA patients (%) NEDA Data from Clinical Trials: 2 year 80 AFFIRM (2001) 60 TEMSO (2004) FREEDOMS (2006) CARE-MS I (2007)* 40 CARE-MS II (2007)* DEFINE (2007) ADVANCE (2009) 20 0 Placebo teriflunomide 14 mg DMF 240 mg bid fingolimod 0.5 mg Peg IFNβ-1a Q2W natalizumab sc IFN β-1a 44 µg tiw alemtuzumab *Data from CARE MS I and II trials present the percentage of patients who achieved NEDA between Year 1 and Year 2, all other trials present the cumulative percentage of NEDA patients over 2 years
35 *Trial data are not comparable owing to different definitions of relapse or EDSS progression and frequency or type of MRI Treatment Increases Odds of Achieving NEDA over 2 Years* Alemtuzumab 2.4* *DAF vs IFN -1 sc Teriflunomide 1,6 Additive effect to that of IFN -1 sc? IFNb1a sc 3,41 Fingolimod 2,54 Cladribine 2,91 Natalizumab 5, Increase Odds of NEDA of Treatment over Placebo
36 Sustaining NEDA: CLIMB Study 215 patients with CIS/RMS followed for at least 7 years with annual MRI & bi-annual clinical assessment NEDA at 2 years had a positive predictive value of 78.3% for no progression ( EDSS 0.5) at 7 years Rotstein DL et al. JAMA Neurol :
37 NEDA: A Potentially Better Outcome Measure? What sort of relative or absolute difference in NEDA would be meaningful in a clinical trial? How do we insure meaningfulness of change? All disease activity cannot be dominated by MRI? If events in populations are becoming less meaningful (due in part to earlier identification and change in diagnostic criteria), is being free of these less meaningful events more meaningful?
38 Conclusions Changing MS population Steady reduction in outcome measures of disease activity so difficult to determine efficacy based on clinical event rates Effective treatments are becoming mainstream obviating the ability to use a placebo comparator Is it now a reasonable goal for clinicians to strive for a state of no evidence of disease activity (NEDA)? A NEDA composite should be considered as a primary outcome measure for forthcoming trials, especially if using active comparators
39 Treatment Challenges: Benefit vs. Risk M o A Historical Therapies Some advantages might be worth the risks Emerging Therapies
40 6 October Barcelona, Spain MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION
MS Academia: Multiple sclerosis advanced course
13 September 2016 - London, UK MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Robert J. Fox Assessment of treatment response IMPROVING
More informationProgress in the field
Progress in the field Eva Havrdová Charles University in Prague 1st Medical Faculty and General University Hospital Disclosures Dr. Havrdová has received consulting fees from Actelion, Biogen Idec, Merck,
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org What
More information2013 MS Phenotype Descriptions: Relapsing MS 1
2013 MS Phenotype Descriptions: Relapsing MS 1 Disease-Modifying Therapies? which can be found in its entirety at. Clinically isolated syndrome (CIS) Not Active a Active a,b Relapsing-remitting disease
More informationMitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA Disclosures Consultant and Speaker Bureau member for Biogen-Idec, Pfizer, TEVA Neuroscience, Bayer, EMD Serrono, Questcor, Novartis,
More informationEfficacy convenience of MS treatments. Xavier Montalban Department of Neurology-Neuroimmunology. ECF Baveno 2013
Efficacy convenience of MS treatments Xavier Montalban Department of Neurology-Neuroimmunology ECF Baveno 2013 Disclaimer Dr. Montalban has received speaking honoraria and travel expenses for scientific
More informationEAN Amsterdam June 23-27, 2017
EAN 2017 Amsterdam June 23-27, 2017 MS Nowadays-new goals Giancarlo Comi Dept. of Neurology & Institute of Experimental Neurology Università Vita Salute S.Raffaele, Milano European Charcot Foundation Disclosure
More informationCurrent Enrolling Clinical Trials
ASSESS RRMS patients with active disease who are still able to walk. Mariko Kita MD Description of Study/Trial: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety
More informationAdvances in the Management of Multiple Sclerosis: A closer look at novel therapies. Disclosures
Advances in the Management of Multiple Sclerosis: A closer look at novel therapies Lily Jung Henson, MD, MMM, FAAN Chief of Neurology Piedmont Healthcare, Atlanta, GA National Association of Managed Care
More informationThe invisible facets of MS and everyday challenges clinician s perspective. Mar Tintore
The invisible facets of MS and everyday challenges clinician s perspective Mar Tintore Centre d Esclerosi Múltiple de Catalunya (Cemcat). Department of Neurology/Neuroimmunology Hospital Universitari Vall
More informationLife Long Brain Health and DMT Comparative Effectiveness
Life Long Brain Health and DMT Comparative Effectiveness Timothy Vollmer, MD Professor of Neurology University of Colorado Denver Medical Director- RMMSC and Co-Director Rocky Mountain MS Center at CU
More information1996 vs 2013 MS Phenotype Descriptions of Progressive Disease
Learning Objectives Upon completion, participants should be able to: Describe methods of distinguishing among RRMS, SPMS, and PPMS Incorporate available evidence about emerging and recently approved novel
More informationBenefit/Risk Strategies in Selecting Therapeutic Solutions for MS: HCP and Patient Viewpoints
Benefit/Risk Strategies in Selecting Therapeutic Solutions for MS: HCP and Patient Viewpoints 1 Learning Objectives Review the benefit/risk strategies in selecting therapy for MS patients while assessing
More informationUpdate in Multiple Sclerosis
Update in Multiple Sclerosis Kyle Smoot, MD Providence MS Center Portland, OR 1 Disclosures Research funds from Biogen. Consulting fees from Acorda, Biogen, EMDSerono, Genzyme, Novartis, and Teva. 2 Outline
More informationEvidence from bone marrow transplantation
Evidence from bone marrow transplantation Gianluigi Mancardi Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Ospedale Policlinico San Martino, University
More informationPer Soelberg Sørensen
Per Soelberg Sørensen Danish Multiple Sclerosis Center Department of Neurology Rigshospitalet, University of Copenhagen Copenhagen, Denmark Declared receipt personal compensation for serving on scientific
More informationA Glimpse at Immunomodulators in MS
A Glimpse at Immunomodulators in MS An Interview with Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC Multiple Sclerosis Research Unit, University of Ottowa, Ottowa Canada Ottawa Hospital Research Institute,
More informationNeurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy
Nicola De Stefano Neurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy Declared receipt of honoraria or consultation fees from Novartis,
More informationThe Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
More informationInnovazione e personalizzazione nella terapia della SM. Rocco Totaro Centro per la Diagnosi e Cura delle Malattie Demielinizzanti L Aquila
Innovazione e personalizzazione nella terapia della SM Rocco Totaro Centro per la Diagnosi e Cura delle Malattie Demielinizzanti L Aquila Which are the objectives of MS treatment? «Historically»
More informationPresented at the Annual Congress of ECTRIMS, October 11, 2018, Berlin, Germany
Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mab), in Patients with Relapsing Forms of Multiple Sclerosis
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationClinician s view of Benefit-Risk
Clinician s view of Benefit-Risk Gordon Francis, MD Novartis, Clinical Development Clinician s View of Benefit-Risk: a need for reliable metrics A tale of 3 drugs Natalizumab MS Crohn s Disease Fingolimod
More informationActivity presentations are considered intellectual property.
Activity presentations are considered intellectual property. Activity presentations are considered intellectual property and are for viewing purposes only. No content should be copied or reproduced in
More informationHot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018
Hot Topics Multiple Sclerosis Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018 Disclosures Natalie Parks has received compensation from Biogen, EMD Serono, Roche, and Sanofi
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationLe Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono
Le Hua, MD Le Hua, MD, is a staff neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV. She is involved in clinical trials assessing new therapies for the treatment of MS and
More informationCarolyn Taylor, M.D. Swedish Neuroscience Center
Carolyn Taylor, M.D. Swedish Neuroscience Center When should disease modifying therapy be discontinued in MS? Should we be using aggressive treatments earlier in the MS disease course and reserving the
More informationWorkshop II. How to manage highly active MS patients in practice?
Workshop II How to manage highly active MS patients in practice? Gavin Giovannoni Department of Neurology Institute of Cell and Molecular Science Queen Mary University London & Barts and The London NHS
More informationHealth-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
CNS Drugs (2017) 31:585 602 DOI 10.1007/s40263-017-0444-x REVIEW ARTICLE Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs Peter Joseph Jongen 1,2 Published
More informationProgress in MS: Current and Emerging Therapies. Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada Today s Discussion Natural History and Classification of MS Treating MS Management
More informationPediatric MS treatments: What do you start with, when do you switch?
Pediatric MS treatments: What do you start with, when do you switch? Tim Lotze, M.D. Associate Professor of Pediatric Neurology Texas Children s Hospital Baylor College of Medicine Disclosures Clinical
More informationMEDIA BACKGROUNDER. Teriflunomide: A novel oral drug being investigated for the treatment of Multiple Sclerosis (MS)
MEDIA BACKGROUNDER Teriflunomide: A novel oral drug being investigated for the treatment of Multiple Sclerosis (MS) 1. Background Teriflunomide is a new oral disease-modifying therapy (DMT), discovered
More informationMULTIPLE SCLEROSIS - REVIEW AND UPDATE
MULTIPLE SCLEROSIS - REVIEW AND UPDATE Luka Vlahovic, MD Neuroimmunology/Multiple Sclerosis Creighton University Medical Center MS is primary demyelinating disease of the central nervous system. MS is
More informationTreating MS. New medicines, strong evidence, better practice? September 2015
Treating MS New medicines, strong evidence, better practice? September 2015 1 A Treatment Revolution for RRMS Over the past 20 years there has been a revolution in treatments for relapsing remitting MS
More informationEfficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
RESEARCH ARTICLE Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials Vissia Viglietta 1, David Miller 2, Amit Bar-Or 3, J.
More informationMultiple Sclerosis: Emerging Therapies
Multiple Sclerosis: Emerging Therapies Bruce Cree, MD, PhD, MCR Conflicts of Interest EMD Serono: Grant support ovartis: Adviser, Clinical Trial Participant What are the Future Considerations for MS Therapies?
More informationBiologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS
Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS Disclosure Information Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS I have no financial
More informationBruce Cree, MD, PhD, MCR. BG-12 Has Shown Nrf2 Pathway. Activation. DEFINE (BG-12/Dimethyl Fumarate) : Study Design
MS Therapies Update 212 Bruce Cree, MD, PhD, MCR BG12 Alemtuzumab Daclizumab BAF312 Erythropoetin Outline Fingolimod IFN β-1a Natalizumab Oral solumedrol Duloxetine O BG-12 Has Shown Nrf2 Pathway O OH
More informationProgram Highlights. A multidisciplinary AAN working group identified areas for improvement in the diagnosis and management of patients with MS
CasePerspectives: Illuminating Dark Pathways in Complex MS Cases Program Highlights Stephen Krieger, MD Associate Professor of Neurology Corinne Goldsmith Dickinson Center for MS Director, Neurology Residency
More informationTREATING MULTIPLE SCLEROSIS The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center
TREATING MULTIPLE SCLEROSIS 2018 The Current Disease Modifying Therapies Beverly Gilder, M.D. Blue Sky Neurology MS Center Welcome Thank you for joining us! Today you will learn about MS treatment choices
More informationConsortium of Multiple Sclerosis Centers 2015 Abstract #3485
Alemtuzumab (ALE) Improves Disability After Switch from Other Disease Modifying Therapies in a High Disability, Treatment Refractory Relapsing MS Cohort Consortium of Multiple Sclerosis Centers 2015 Abstract
More informationPatient 1: 31-Year-Old Female. Fingolimod treatment
Cell Counts (10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Lymphocyte Pharmacodynamics and Safety of Use in Patients Previously
More informationTreatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis(review)
Cochrane Database of Systematic Reviews Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis(review) Filippini G, Del Giovane C, Clerico M, Beiki
More informationAPPENDIX D SASKATCHEWAN MS DRUGS PROGRAM
APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM PROCEDURE FOR OBTAINING COVERAGE OF MS DRUGS UNDER THE DRUG PLAN Requests are initiated by a physician. The patient and physician complete the application form
More informationEndpoints in a treatment trial in NMO: Clinician s view. Anu Jacob Consultant Neurologist The Walton Centre, Liverpool,UK
Endpoints in a treatment trial in NMO: Clinician s view Anu Jacob Consultant Neurologist The Walton Centre, Liverpool,UK 1 The greatest challenge to any thinker is stating the problem in a way that will
More informationTechnology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493
Cladribine tablets for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493 NICE 2018. All rights reserved. Subject to Notice
More informationTreating MS patients earlier in the disease progression may affect long-term outcomes 1-4
Treating MS patients earlier in the disease progression may affect long-term outcomes 1-4 TIME DISEASE ONSET EARLY TREATMENT NATURAL COURSE OF MS LATER TREATMENT DISABILITY INCREASE The disease activity
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective December 9, 2013 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationGiancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis
COMPARISON OF EARLY AND DELAYED ORAL LAQUINIMOD IN PATIENTS WITH RELAPSING- REMITTING MULTIPLE SCLEROSIS: EFFECTS ON DISABILITY PROGRESSION AT 36 MONTHS IN THE ALLEGRO TRIAL Giancarlo Comi, M.D. On Behalf
More informationUpdates to the Alberta Drug Benefit List. Effective August 1, 2018
Updates to the Alberta Drug Benefit List Effective August 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
More informationPositive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Media Release Basel 21 December 2016 Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational
More informationNeuroimaging and Other Biomarkers. MRI for Diagnosis, Prognosis and Treatment Decisions in MS
Neuroimaging and Other Biomarkers MRI for Diagnosis, Prognosis and Treatment Decisions in MS Eric Klawiter, MD MSc Massachusetts General Hospital May 30, 2014 Disclosures and Funding Disclosures: Consulting
More informationPATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M / F Year Month Day
Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 6 PATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M
More informationAchieving New Treatment Goals in Multiple Sclerosis Strategies for Initial Treatment Selection and Patient Engagement. Dayton, OH
A CME/CE-certified Symposium held in conjunction with the 2018 Annual Meeting of the CMSC Jointly provided by: In collaboration with: This program was supported by an educational grant from Sanofi Genzyme.
More informationTechnology appraisal guidance Published: 28 May 2014 nice.org.uk/guidance/ta312
Alemtuzumab for treating relapsing-remitting multiple sclerosis Technology appraisal guidance Published: 28 May 2014 nice.org.uk/guidance/ta312 NICE 2017. All rights reserved. Subject to Notice of rights
More informationDouglas L. Arnold 1,2, Peter A. Calabresi 3, Bernd C. Kieseier 4,5, Shifang Liu 5, Xiaojun You 5, Damian Fiore 5 and Serena Hung 5*
Arnold et al. BMC Neurology (2017) 17:29 DOI 10.1186/s12883-017-0799-0 RESEARCH ARTICLE Open Access Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence
More informationCost-effectiveness of cladribine (Mavenclad ) for the
Cost-effectiveness of cladribine (Mavenclad ) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features The NCPE has issued a recommendation
More informationSwitching from natalizumab to fingolimod: an observational study
Acta Neurol Scand 2013: 128: e6 e10 DOI: 10.1111/ane.12082 Ó 2013 John Wiley & Sons A/S ACTA NEUROLOGICA SCANDINAVICA Clinical Commentary Switching from natalizumab to fingolimod: an observational study
More informationLong-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing remitting multiple sclerosis: the CLARITY Extension study
753365TAN0010.1177/1756285617753365Therapeutic Advances in Neurological DisordersG Comi, S CooK research-article2018 Therapeutic Advances in Neurological Disorders Original Research Long-term effects of
More informationMedication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationAssessing the Potential Implications of the Topographical Model of Multiple Sclerosis on Patient Practitioner Communication and Treatment Selection
CME Assessing the Potential Implications of the Topographical Model of Multiple Sclerosis on Patient Practitioner Communication and Treatment Selection Course Director Stephen Krieger, MD, FAAN Corinne
More informationShutting Down MS: New Insights on Induction, Escalation, Oral Agents, and Monitoring
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationAnisha Keshavan. Roland Henry, PhD. Proportion of Patients (%) Rituximab 2000mg (n=66) Placebo (n=35)
Two Faces of Multiple Sclerosis February 8, 217 5 T H A N N U A L R E C E N T A D V A N C E S I N N E U R O L O G Y B CELL THERAPY FOR MULTIPLE SCLEROSIS: A NEW DAY? Inflammation Relapsing MS Anisha Keshavan
More informationA comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo
Original Research Paper A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo Patrick Vermersch, Ernst-Wilhelm Radue, Norman Putzki, Shannon Ritter, Martin
More informationAFFIRM IN FOCUS AN INTERACTIVE OVERVIEW START HERE
AFFIRM IN FOCUS AN INTERACTIVE OVERVIEW START HERE INTENDED USE The information in this module is being provided to you to increase your knowledge and understanding of the AFFIRM a study. Although this
More informationMedia Release. Basel 12 January 2018
Media Release Basel 12 January 2018 Roche s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis First and only approved
More informationObjectives. There Aren t Enough Hours in the Day
There Aren t Enough Hours in the Day Medication monitoring and communication of results Objectives Review the types of testing being ordered on patients receiving therapies other than platforms Discuss
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta441
Daclizumab for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta441 NICE 2017. All rights reserved. Subject to Notice of rights
More informationMultiple Sclerosis. Stanley L Cohan, MD, PhD Providence MS Center Providence Brain and Spine Institute
Stanley L Cohan, MD, PhD Providence MS Center Providence Brain and Spine Institute 1 Stanley Cohan conflicts of interest Research Support: Biogen Idec, Novartis, Mallinkrodt, Genzyme, Sanofi-Aventis, Teva,
More informationMedscape: What do you see as the main clinical implications of your results?
http://www.medscape.com/px/viewindex/more?bucket=columns§ionid=2011 Treatment Optimization for Multiple Sclerosis: An Expert Interview With Mark Freedman, MD Posted 11/10/2004 Editor's Note: Multiple
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION ALEMTUZUMAB (Lemtrada Genzyme Canada) Indication: Relapsing-Remitting Multiple Sclerosis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that alemtuzumab
More informationAssessing treatment outcomes in multiple sclerosis trials and the clinical
1 Assessing treatment outcomes in multiple sclerosis trials and the clinical setting Working title: Outcomes in multiple sclerosis Carmen Tur 1, Marcello Moccia 1,2, Frederik Barkhof 1,3,4,5, Jeremy Chataway
More informationCSF Axonal Injury Markers
CSF Axonal Injury Markers Gavin Giovannoni Barts and The London Disclosures Professor Giovannoni has received personal compensation for participating on Advisory Boards in relation to clinical trial design,
More informationMedia Release. Basel, 10 November 2017
Media Release Basel, 10 November 2017 Roche s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis If approved, OCREVUS
More informationAuthor s Accepted Manuscript
Author s Accepted Manuscript Optimizing therapy early in multiple sclerosis: an evidence-based view Tjalf Ziemssen, Nicola De Stefano, Maria Pia Sormani, Bart Van Wijmeersch, Heinz Wiendl, Bernd C. Kieseier
More informationProgressive Multiple Sclerosis
Progressive Multiple Sclerosis Definitions, Clinical Course and Emerging Therapies M. Mateo Paz Soldán, MD, PhD Neurology Service, VA Salt Lake City HCS Assistant Professor of Neurology, University of
More informationPrior Authorization. Drug Name (select from list of drugs shown) Gilenya (fingolomid) Quantity Frequency Strength. Physician Name:
06/01/2016 Prior Authorization Aetna Better Health Michigan Gilenya This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed
More informationNews Release. March 29, 2019
Your Contact Alice McGrail +1 781 738 8791 Investor Relations +49 6151 72 3321 March 29, 2019 FDA Approves MAVENCLAD (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting
More informationORIGINAL ARTICLE EUROPEAN JOURNAL OF NEUROLOGY. Introduction
ORIGINAL ARTICLE Natalizumab improves ambulation in relapsing remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM N. Voloshyna a, E. Havrdova b,
More informationNICE appraisal consultation document for teriflunomide [ID548]
NICE appraisal consultation document for teriflunomide [ID548] Response from the Multiple Sclerosis Trust 9 th October 2013 Please find below comments from the MS Trust in relation to the Appraisal Consultation
More informationMS Trust Comments on the ACD
MS Trust Comments on the ACD Name xxxxxxxxxxx Role other Other role xxxxxxxxxxxxxxxxxx Location England Conflict no Notes Comments on individual sections of the ACD: Section 1 The MS Trust maintains that
More informationTop 10 Research Findings of 2016
Top 10 Research Findings of 2016 NMSS Regional Summit 2017 June 10, 2017 Rebecca Spain, MD, MSPH VA Portland Health Care System Oregon Health & Science University Disclosures Research support: NMSS Department
More informationTreatment Optimization in MS: Canadian MS Working Group Updated Recommendations
REVIEW ARTICLE Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations Mark S. Freedman, Daniel Selchen, Douglas L. Arnold, Alexandre Prat, Brenda Banwell, Michael Yeung, David
More informationClass Update with New Drug Evaluation: Disease-Modifying Drugs for Multiple Sclerosis
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFor HCPs Brain Health: Time Matters
For HCPs Brain Health: Time Matters Gavin Giovannoni Barts and The London Disclosures Professor Giovannoni has received personal compensation for participating on Advisory Boards in relation to clinical
More informationTRANSPARENCY COMMITTEE Opinion 05 March 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 05 March 2014 AUBAGIO 14 mg, film-coated tablet B/28 tablets (CIP: 3400927499890) Applicant: GENZYME SAS INN ATC code
More informationPage 1. Multiple Sclerosis. I have no conflicts of interest. Team Menstrual Cycles Waves to Wine for MS. Overview.
Multiple Sclerosis New Developments Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine University of California, San Francisco I have no conflicts of interest Team Menstrual
More informationCircle Yes or No Y N. [If no, skip to question 8.] 2. Has the patient been compliant with therapy as verified by the prescriber?
06/01/2016 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Tecfidera (MI88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationRisk attitudes and risk perceptions in individuals with multiple sclerosis
Original Article Risk attitudes and risk perceptions in individuals with multiple sclerosis Bonnie I Glanz, Emily Greeke, Allison LaRussa, Fiona Stuart, David J Rintell, Tanuja Chitnis and Brian C Healy
More informationThese points are discussed within Sections A, B and C of our response.
Professor C Longson Director, Centre for Health Technology Evaluation National Institute for Health and Clinical Excellence (NICE) Midcity Place 71 High Holborn London WC1V 6NA 5 th January 2012 Dear Professor
More informationClinical Study Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis International Volume 23, Article ID 89624, 9 pages http://dx.doi.org/.55/23/89624 Clinical Study Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple
More informationTHC:CBD Daily Practice Evidence in MS Spasticity Management: The Moment of Large Databases
THC:CBD Daily Practice Evidence in MS Spasticity Management: The Moment of Large Databases Almirall-Sponsored Satellite Symposium of the 31 st Congress of the European Committee for Treatment and Research
More informationHorizon Scanning Centre July Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line
Horizon Scanning Centre July 2014 Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line SUMMARY NIHR HSC ID: 2635 This briefing is based on information available
More informationEvidence Based Treatment for Multiple Sclerosis: Screening to Treatment
Evidence Based Treatment for Multiple Sclerosis: Screening to Treatment Scott Newsome, DO, MSCS Director, Neurology Outpatient Services Director, Neurology Infusion Center Associate Professor of Neurology
More informationHorizon Scanning Centre July Ocrelizumab for relapsing-remitting multiple sclerosis SUMMARY NIHR HSC ID: 3711
Horizon Scanning Centre July 2014 Ocrelizumab for relapsing-remitting multiple sclerosis SUMMARY NIHR HSC ID: 3711 This briefing is based on information available at the time of research and a limited
More informationTable e-1: Patient Level Baseline Characteristics
Table e-1: Patient Level Baseline Characteristics *= Subject not transplanted on study due to heparin induced thrombocytopenia following mobilization. ALE = Alemtuzumab; AZA = Azathioprine; CY = Cyclophosphamide;
More informationMRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis. E.W. Radue K. Bendfeldt Till Sprenger
MRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis E.W. Radue K. Bendfeldt Till Sprenger Medical Image Analysis Center University Hospital Basel www. miac.ch
More informationMultiple Sclerosis Update
Multiple Sclerosis Update Amanda Stahnke, PharmD, BCACP University of Missouri-Kansas City School of Pharmacy Kansas City Veterans Affairs Honor Annex Kelsey Morris, PharmD University of Kansas Health-System
More informationLaquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
DOI 10.1007/s40120-014-0017-6 REVIEW Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review Channa Kolb-Sobieraj Sahil Gupta Bianca Weinstock-Guttman To view enhanced content go to www.neurologytherapy-open.com
More information